Literature DB >> 15265419

[A pilot study of selective screening for high risk children with inborn error of metabolism using tandem mass spectrometry in China].

Xue-fan Gu1, Lian-shu Han, Xiao-lan Gao, Yan-ling Yan, Jun Ye, Wen-juan Qiu.   

Abstract

OBJECTIVE: The new technology of tandem mass spectrometry is exerting a significant impact on the diagnostics of inborn metabolic errors, and allows to detect a number of these disorders in a single step. The aim of the present study was to establish a dry blood filter paper method for amino acid and acylcarnitine profiles test using tandem mass spectrometry and to apply the method for selective screening in high risk children with inborn error of metabolism.
METHOD: The study group consisted of 104 high risk cases of inborn error of metabolism from 5 pediatric hospitals in Shanghai and Beijing were tested from November 2002 to June 2003; 77 were males and 27 females, the means age was 4.8 +/- 4.2 years. These patients had mental retardation, slow development, psychological abnormalities, muscle hypotonia, jaundice, hepatosplenomegaly, recurrent vomiting, and convulsion. Laboratory examinations suggested metabolic acidosis, hypoglycemia, hyperammonemia and hyperlactacidemia. Phenylketonuria was excluded in this study by routine phenylalanine screening. The control group consisted of 308 children, 170 males and 138 females. The blood was collected on filter paper, punched and extracted into methanol solution with stable isotope labeled internal standards, then derivatized with butanolic-HCl. After preparation, the samples were analyzed by tandem mass spectrometry (API 2000).
RESULTS: Ten of 104 patients (9.6%) were positive in our selective screening program, including one with tyrosinemia, one with homocystinuria, one with hyperornithinemia, two with methylmalonic acidemia, one with propionic acidemia, one with 3-hydroxy-3-methylglutaryl-CoA lyase deficiency, two with medium chain acyl-CoA dehydrogenase deficiency, and one with carnitine palmitoyl transferase type II deficiency.
CONCLUSION: The authors established a fast, accurate and sensitive tandem mass spectrometry method for amino acid and acylcarnitine profiles analysis, nearly 30 metabolic diseases including amino acid disorders, organic acid disorders and fatty acid oxidation disorders could be detected, most of the diseases that cause death and disability represent preventable entities by early diagnosis and treatment. The results indicated the importance of selective screening for high risk patients with inborn error of metabolism.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15265419

Source DB:  PubMed          Journal:  Zhonghua Er Ke Za Zhi        ISSN: 0578-1310


  5 in total

1.  Spectrum analysis of common inherited metabolic diseases in Chinese patients screened and diagnosed by tandem mass spectrometry.

Authors:  Lianshu Han; Feng Han; Jun Ye; Wenjuan Qiu; Huiwen Zhang; Xiaolan Gao; Yu Wang; Wenjun Ji; Xuefan Gu
Journal:  J Clin Lab Anal       Date:  2014-05-05       Impact factor: 2.352

2.  Selective screening for inborn errors of metabolism on clinical patients using tandem mass spectrometry in China: a four-year report.

Authors:  L S Han; J Ye; W J Qiu; X L Gao; Y Wang; X F Gu
Journal:  J Inherit Metab Dis       Date:  2007-03-08       Impact factor: 4.982

3.  Screening for inborn errors of metabolism in high-risk children: a 3-year pilot study in Zhejiang Province, China.

Authors:  Xinwen Huang; Lili Yang; Fan Tong; Rulai Yang; Zhengyan Zhao
Journal:  BMC Pediatr       Date:  2012-02-24       Impact factor: 2.125

4.  Diagnosis and therapeutic monitoring of inborn errors of metabolism in 100,077 newborns from Jining city in China.

Authors:  Chi-Ju Yang; Na Wei; Ming Li; Kun Xie; Jian-Qiu Li; Cheng-Gang Huang; Yong-Sheng Xiao; Wen-Hua Liu; Xi-Gui Chen
Journal:  BMC Pediatr       Date:  2018-03-13       Impact factor: 2.125

5.  Cost-effectiveness analysis of newborn screening by tandem mass spectrometry in Shenzhen, China: value and affordability of new screening technology.

Authors:  Mingren Yu; Juan Xu; Xiaohong Song; Jiayue Du
Journal:  BMC Health Serv Res       Date:  2022-08-15       Impact factor: 2.908

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.